These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8397766)

  • 21. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic immunotoxin therapy of cancer: advances and prospects.
    Wawrzynczak EJ
    Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.
    Marches R; Mota G; Margineanu M; Stavri H; Savi G; Nicolae M; Bancu A; Moraru I
    Neoplasma; 1990; 37(5):573-8. PubMed ID: 2234217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibody therapy for solid tumors.
    Green MC; Murray JL; Hortobagyi GN
    Cancer Treat Rev; 2000 Aug; 26(4):269-86. PubMed ID: 10913382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-based therapeutics in oncology.
    Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of monoclonal antibodies in the diagnosis and therapy of cancer.
    Vaickus L; Foon KA
    Cancer Invest; 1991; 9(2):195-209. PubMed ID: 1863875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotherapy of ovarian cancer.
    Lidor Y; Bast RC
    Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
    MacDonald GC; Glover N
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted cancer treatment.
    Goldenberg DM
    Immunol Today; 1989 Sep; 10(9):286-8. PubMed ID: 2590380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotoxins containing ricin or its A chain.
    Vitetta ES; Thorpe PE
    Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technology evaluation: SGN-15, Seattle Genetics Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
    Schmidberger H; King L; Lasky LC; Vallera DA
    Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.